Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase trials in relapsed patients to a viable therapeutic approach with predictable efficacy and low toxicity for broad application among patients with high unmet need is currently complicated by product heterogeneity res...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Gardner, Rebecca A., Finney, Olivia, Annesley, Colleen, Brakke, Hannah, Summers, Corinne, Leger, Kasey, Bleakley, Marie, Brown, Christopher, Mgebroff, Stephanie, Kelly-Spratt, Karen S., Hoglund, Virginia, Lindgren, Catherine, Oron, Assaf P., Li, Daniel, Riddell, Stanley R., Park, Julie R., Jensen, Michael C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482103/
https://ncbi.nlm.nih.gov/pubmed/28408462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-02-769208
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars